|
| Tuesday, January 26, 2021 |
|
|
Eisai Listed as a Global 100 Most Sustainable Corporation for the Fifth Time |
| Eisai Co., Ltd. announced that it has been listed in the 2021 Global 100 Most Sustainable Corporations in the World (Global 100), a global ranking by Canada-based media and investment advisory company, Corporate Knights, Inc. more info >> |
|
| Tuesday, January 12, 2021 |
|
|
Eisai to Present Abstracts on Lenvatinib at 2021 Gastrointestinal Cancers Symposium |
| Eisai Co., Ltd. has announced that presentations on a series of abstracts highlighting updates on its in-house discovered lenvatinib mesylate (product name: LENVIMA, the orally available kinase inhibitor, "lenvatinib") will be given at the Gastrointestinal Cancers Symposium Virtual Meeting, from January 15 to 17, 2021. more info >> |
|
| Friday, December 18, 2020 |
|
|
Eisai Completes Construction of the 5th Manufacturing Building at Kawashima Industrial Park in Japan |
| Eisai Co., Ltd. announced that it has completed construction of the 5th manufacturing building at the Kawashima Industrial Park located in Gifu Prefecture, Japan. more info >> |
|
| Thursday, December 17, 2020 |
|
|
LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combination Demonstrated Statistically Significant Improvement in OS, PFS and ORR |
| These positive results were observed in the mismatch repair proficient (pMMR) subgroup and the intention-to-treat (ITT) study population, which includes both patients with endometrial carcinoma that is pMMR as well as patients whose disease is microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR). more info >> |
|
| Friday, December 11, 2020 |
|
|
Eisai: Biogen Files New Drug Application for Aducanumab in Japan |
| Biogen and Eisai, Co., Ltd. (Tokyo, Japan) announced that Biogen has submitted a Japanese New Drug Application (J-NDA) to the Ministry of Health, Labor and Welfare (MHLW) for aducanumab, an investigational therapy for Alzheimer's disease. more info >> |
|
| Friday, December 4, 2020 |
|
|
Eisai to Present Abstracts on Oncology Products and Pipeline at 43rd Annual San Antonio Breast Cancer Symposium |
| The results of analysis evaluating eribulin in the clinical practice in a subgroup of patients with metastatic breast cancer with a poor prognosis, in the United States, (Abstract No: PS13-37) will be published. more info >> |
|
| Monday, November 30, 2020 |
|
|
Eisai to Present Latest Data on Perampanel at the 74th American Epilepsy Society Annual Meeting |
| Eisai Co., Ltd. announced today that the company will present the latest data on its in-house discovered and developed anti-epileptic agent (AED) perampanel (product name: Fycompa), at the 74th American Epilepsy Society Annual Meeting (AES2020), to be held virtually from December 4 to 8, 2020. more info >> |
|
|
Eisai and Wren Therapeutics Enter Into Research Collaboration Agreement for Drug Discovery for Synucleinopathies |
| Eisai Co., Ltd. and Wren Therapeutics Ltd. today announced that the companies have entered into an exclusive research collaboration agreement aiming to advance the discovery of novel small molecules that target alpha-synuclein for the potential treatment of synucleinopathies including Parkinson's disease and dementia with Lewy bodies. more info >> |
|
| Friday, November 27, 2020 |
|
|
AbbVie and Eisai Announce an approval for additional indication of HUMIRA |
| This indication counts for HUMIRA's 12th indication in Japan and makes HUMIRA the world's first drug indicated for the treatment of PG. more info >> |
|
| Wednesday, November 18, 2020 |
|
|
Eisai Selected for Membership in Dow Jones Sustainability Asia Pacific Index 2020 for Seventh Time |
| Eisai Co., Ltd. announced today that it has been selected for a membership in the Dow Jones Sustainability Asia Pacific Index (DJSI Asia Pacific), the Asia Pacific version of the Dow Jones Sustainability Indices (DJSI), which are a family of premier global indices for socially responsible investment (SRI). This marks Eisai?s seventh selection. more info >> |
|
|
|
